Lang, P.A., Recher, M., Honke, N., Scheu, S., Borkens, S., Gailus, N., Krings, C., Meryk, A., Kulawik, A., Cervantes-Barragan, L., Van Rooijen, N., et al. (2010) Tissue Macrophages Suppress Viral Replication and Prevent Severe Immunopathology in an Interferon-Independent Manner in Mice. Hepatology, 52, 25-32.
https://doi.org/10.1002/hep.23640

has been cited by the following article:

• TITLE: SARS-COV-2 Induce Pulmonary Injury from Basic to Clinical Research

  AUTHORS: Jinguo Zhu

  KEYWORDS: COVID-19, SARS-CoV-2, Pulmonary Injury, Clinical Manifestation, Treatment Strategies

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.12 No.3, March 31, 2022

  ABSTRACT: The SARS-CoV-2 has infected over 194,909,000 cases and over 4,170,000 deaths in the world before the end of July 2021. The virus attacks human alveoli and induces severe lung injury (COVID-19 disease) and spreads rapidly. The mechanisms of COVID-19 disease are unclear. To better understand this disease, This review analyzes the SARS-CoV-2 biological characteristics, insights the effect of alveolar epithelium and its adjacent microvascular endothelium, investigates human host cells immune response and immunothrombosis. Explains clinical manifestations of COVID-19 associated lung injury. It may be helpful for development management strategies for COVID-19 associated pulmonary damage.